Drug intelligence / Profile preview

SMART-103

Development stage: Preclinical
Lead developer: Smart Immune
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intraventricular, Intracavitary

Overview

SMART-103 is a preclinical **T lymphocyte replacement therapy** being developed by **Smart Immune** for immune system diseases and immune disorders. Based on the available information, it is a cell therapy intended to restore or replace functional T-lymphocyte immunity rather than a conventional small-molecule or antibody drug. Publicly available details are limited, and no more specific molecular target, administration route, dosage form, or branded product name was identified from the provided context.

Beyond the preview

Go deeper on SMART-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMART-103.

Explore the full profile